Post-stroke Depression: Epidemiology, Diagnosis, Risk Factors, and Management

Sangam, Shreya

doi:10.4172/2329-6895.1000394

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7] Another study examined the direct cost of stroke management and suggested that the economic burden may be higher in stroke management. [8] Post-stroke depression is a global issue among stroke survivors and sometimes unrecognised and undertreated. It was noted that if proper attention is given to stroke patients, some of the causes may be prevented.…”

Section: Annals Of Health Research Volume 7 Issue No 3 2021__________________________303mentioning

confidence: 99%

“…It was noted that if proper attention is given to stroke patients, some of the causes may be prevented. [8] Some of the risk factors are modifiable; these include high blood pressure, smoking, diabetes mellitus, hypercholesterolaemia, physical inactivity and obesity, carotid or other artery diseases, certain blood disorders, excessive alcohol intake, illegal drug use and sleep apnoea, among others. Factors that cannot be controlled include increasing age, gender, heredity and race, and prior stroke.…”

Section: Annals Of Health Research Volume 7 Issue No 3 2021__________________________303mentioning

confidence: 99%

See 1 more Smart Citation

Beta Inflated Regression Models on the Physical and Mental Health of Nigerian Stroke Survivors

Oritogun¹,

Oyewole

2021

Ann Health Res

View full text Add to dashboard Cite

Background: Stroke is one of the major public health problems worldwide. Physical and mental health data of stroke survivors are often expressed in proportions. Therefore, the Beta Regression models family for data between zero and one will be appropriate. Objectives: To identify a suitable model and the likely risk factors of physical and mental health of stroke survivors. Method: Secondary data of stroke survivors from two tertiary health Institutions in Ogun State, Nigeria, were analysed. Inflated Beta (BEINF) and Inflated-at-one-Beta (BEINF1) models were compared using Deviance (DEV), Akaike Information Criterion (AIC) and Bayesian Information Criteria (BIC) for model selection. The model with minimum DEV, AIC and BIC was considered to be better. Results: The deviance (-86.0604,), AIC (-46.0604) and BIC (6.4391) values of the BEINF1 model for physical health and the deviance (-20.1217), AIC (19.8783) and BIC (72.3778) values of BEINF1 model for mental health were smaller than BEINF models. Therefore, BEINF1 was the better model to identify the health risk factors of stroke survivors. Age, marital status, diastolic blood pressure, disability duration and systolic blood pressure had a significant association with physical health, while BMI had a significant positive association with mental health. Conclusion: The beta-inflated-at-one (BEINF1) model is suitable for identifying health risk factors of stroke survivors when the outcome variable is a proportion. Both demographic and clinical characteristics were significantly associated with the health of stroke survivors. This study would assist researchers in knowing the appropriate model for analysing proportion or percentage response variables.

show abstract

Section: Annals Of Health Research Volume 7 Issue No 3 2021__________________________303mentioning

confidence: 99%

Section: Annals Of Health Research Volume 7 Issue No 3 2021__________________________303mentioning

confidence: 99%

Beta Inflated Regression Models on the Physical and Mental Health of Nigerian Stroke Survivors

Oritogun¹,

Oyewole

2021

Ann Health Res

View full text Add to dashboard Cite

show abstract

“…Despite the acknowledged negative impact on social functional recovery and disease prognosis, PSD is consistently disregarded in clinical practice. Evidence highlights that early intervention of antidepressant therapies in stroke patients presenting no depression symptoms decreases the risk of developing depression [ 8 ]. Hence, it is crucial to provide safer and more effective medications to alleviate the health and financial burden caused by PSD.…”

Section: Introductionmentioning

confidence: 99%

The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial

Yan,

2024

BMC Psychiatry

View full text Add to dashboard Cite

Objectives This study aims to evaluate the safety and efficacy of escitalopram and sertraline in post-stroke depression (PSD) patients, to provide more reliable therapeutics for cardiovascular and psychiatric clinical practice. Methods We recruited 60 patients (aged 40–89 years old) with an ICD-10 diagnosis of PSD, who were then randomly assigned to two groups and treated with flexible doses of escitalopram (10 to 20 mg/day, n = 30) or sertraline (50 to 200 mg/day, n = 30) for consecutive 8 weeks, respectively. The 24-item Hamilton Depression Rating Scale (HAMD-24), the 14-item Hamilton Anxiety Rating Scale (HAMA-14), the Treatment Emergent Symptom Scale (TESS), the Montreal Cognitive Assessment Scale (MOCA), and the Activity of Daily Living scale (ADL) were used to assess patients before, during, and after treatment for depression, anxiety, adverse effects, cognitive function, and daily living activities. Repeated measures ANOVA, the Mann–Whitney U test, the chi-square test (χ2), or Fisher’s exact test was employed to assess baseline demographics, response rate, adverse effects rate, and changes in other clinical variables. Results Significant reduction in HAMD-24 and HAMA-14 scores was evaluated at baseline, as well as 1, 3, 4, 6, and 8 weeks of drug intervention (p < 0.01). There was a significant group difference in post-treatment HAMD-24 scores (p < 0.05), but no difference was observed in HAMA-14 scores (p > 0.05). Further analysis showed a significant variance in the HAMD-24 scores between the two groups at the end of the first week (p < 0.01). The incidence of adverse effects in both patient groups was mild, but there was a statistically significant difference between the two groups (p < 0.05). The improvement in cognitive function and the recovery of daily living abilities were comparable between both groups (p > 0.05). Conclusion Escitalopram and sertraline showed comparable efficacy for anxiety symptoms, cognitive function, and daily living abilities in PSD patients. In addition, escitalopram was more appropriate for alleviating depressive symptoms. To validate the conclusion, trials with a larger sample size are in demand in the future. The registration number is ChiCTR1800017373.

show abstract

Neuropsychiatric symptoms among young stroke survivors—frequency, patterns, and associated factors

2021

View full text Add to dashboard Cite

Post-stroke Depression: Epidemiology, Diagnosis, Risk Factors, and Management

Cited by 7 publications

References 0 publications

Beta Inflated Regression Models on the Physical and Mental Health of Nigerian Stroke Survivors

Beta Inflated Regression Models on the Physical and Mental Health of Nigerian Stroke Survivors

The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial

Neuropsychiatric symptoms among young stroke survivors—frequency, patterns, and associated factors

Contact Info

Product

Resources

About